Daniel Tillett
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Daniel Tillett
Chief Scientific Officer, Executive Director / Race Oncology
Dr Daniel Tillett is the founder and chief executive of Nucleics, a private Australian biotechnology company producing and selling DNA sequencing software to the genomics industry.
Dr Tillett has over 20 years of commercial experience in the biotech industry in project management, sales and marketing, IP management, fund raising and startup investing.
He was previously a senior lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, microbiology, bioinformatics and cancer.
Dr Tillett has more than 40 scientific publications and granted patents in molecular biology, microbiology, genetics and biochemistry.
Dr Tillett has over 20 years of commercial experience in the biotech industry in project management, sales and marketing, IP management, fund raising and startup investing.
He was previously a senior lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, microbiology, bioinformatics and cancer.
Dr Tillett has more than 40 scientific publications and granted patents in molecular biology, microbiology, genetics and biochemistry.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 723rd | Thomson Resources | 0% | -31% |
| 1382nd | Nagambie Resources | -44% | -18% |
| 1622nd | Race Oncology | -60% | 60% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 905th |  | Race Oncology | $3.1m |
| 1069th | | Security Matters | $318k |
| 1072nd | | Nagambie Resources | $293k |
| 1074th | | Thomson Resources | $290k |
| 1076th | | Analytica | $282k |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Chief Scientific Officer, Executive Director, Race Oncology | 03 Nov 2020 |
